KPRX · XBRL financial data

Kiora Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KPRX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0	0*	16,000	20	0	0*	0	0	0	0*	—	—
Research and development	1,085	1,112*	1,494	907	1,317	4,125*	2,532	2,590	2,730	2,928*	2,124	2,077
General and administrative	1,416	881*	1,296	1,538	1,381	1,327*	1,489	1,354	1,444	1,458*	1,612	1,384
Total operating expenses	5,919	2,119*	2,778	2,565	3,602	2,565*	2,330	2,396	794	7,310*	2,510	2,214
Operating income (loss)	(5,919)	(2,119)*	13,222	(2,545)	(3,602)	(2,565)*	(2,330)	(2,396)	(794)	(7,310)*	(2,510)	(2,214)
Interest income	—	year only	223	342	—	year only	277	225	—	year only	—	—
Interest expense	—	year only	—	—	—	year only	—	—	—	year only	—	—
Other income (expense)	106	(66)*	8	(19)	(60)	97*	(16)	(94)	(24)	(27)*	(47)	(11)
Income tax expense (benefit)	—	year only	0	0	0	2,065*	123	(112)	(643)	(650)*	0	0
Net income (loss)	(5,763)	(2,269)*	13,453	(2,222)	(3,413)	(4,224)*	(2,193)	(2,152)	27	(6,517)*	(2,418)	(2,079)
Earnings per share, basic‡ USD per share	(8.01)	—	4.68	(0.53)	(0.81)	—	(0.52)	(0.54)	0.01	(1.56)*	(0.58)	(0.34)
Earnings per share, diluted‡ USD per share	(8.01)	—	3.42	(0.53)	(0.81)	—	(0.52)	(0.54)	0.01	(1.69)*	(0.58)	(0.34)
Weighted average shares, basic‡ thousands of shares	790	—	2,882	4,171	4,215	4,216*	4,217	3,989	4,290	4,170*	4,175	6,178
Weighted average shares, diluted‡ thousands of shares	790	—	3,892	4,171	4,215	4,221*	4,217	3,989	4,362	3,849*	4,175	6,178

‡ Per-share figures and share counts are adjusted for the 1-for-9.000009000009 stock split (June 2024); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (KPRX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	5,400	2,455	31,276	6,575	5,637	3,792	3,771	1,028	5,509	8,697	10,955	7,077
Short-term investments	—	0	—	21,243	23,398	23,000	20,335	19,638	13,867	8,393	2,917	9,762
Accounts receivable	—	0	190	1,341	1,783	601	1,338	2,418	1,213	1,523	1,544	1,091
Prepaid and other current assets	—	233	207	340	470	2,042	942	957	650	1,142	1,206	1,127
Total current assets	6,983	4,738	33,482	31,831	31,653	29,706	27,107	24,737	22,694	21,748	18,683	21,263
Property and equipment, net	39	8	13	63	63	5	5	107	102	92	87	100
Right-of-use asset	19	107	94	82	73	57	152	349	318	286	301	261
Total assets	15,896	13,712	42,440	40,814	38,509	36,484	34,020	31,946	29,863	24,253	21,227	23,776
Accounts payable	125	206	323	269	660	416	942	283	241	1,060	595	216
Accrued liabilities	1,462	1,381	1,222	1,345	1,714	4,589	3,522	2,540	2,154	2,407	2,025	1,982
Total current liabilities	2,101	1,634	1,593	1,656	3,528	6,009	5,275	3,186	2,580	3,631	2,798	2,370
Lease liability, non-current	0	60	46	40	39	34	87	287	248	204	195	161
Total liabilities	7,792	7,602	7,536	7,713	8,479	10,725	10,319	9,818	7,453	8,127	7,293	6,919
Accumulated deficit	(144,708)	(146,977)	(133,524)	(135,745)	(139,159)	(143,382)	(145,575)	(147,728)	(147,701)	(154,217)	(156,635)	(158,714)
Total stockholders' equity	8,104	6,110	34,904	33,102	30,030	25,760	23,700	22,127	22,411	16,127	13,935	16,857
Total liabilities and equity	15,896	13,712	42,440	40,814	38,509	36,484	34,020	31,946	29,863	24,253	21,227	23,776
Common shares outstanding (cover page)‡ thousands of shares	854	2,917	2,917	2,971	3,001	3,001	3,044	3,433	3,678	3,951	4,432	4,424

‡ Per-share figures and share counts are adjusted for the 1-for-9.000009000009 stock split (June 2024); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (KPRX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(5,763)	(2,269)*	13,453	(2,222)	(3,413)	(4,224)*	(2,193)	(2,152)	27	(6,517)*	(2,418)	(2,079)
Stock-based compensation	265*	182*	175	150*	171*	160*	149	263*	254*	234*	210	109*
Depreciation and amortization	11*	8*	5	6*	2*	6*	0	3*	11*	11*	11	11*
Net cash from operating activities	(2,521)*	(2,581)*	13,625	(3,733)*	920*	(2,252)*	(2,704)	(3,803)*	(1,273)*	(2,180)*	(3,161)	(1,892)*
Purchases of property and equipment	0*	0*	—	—	0*	(45)*	0	32*	0*	78*	5	23*
Net cash from investing activities	0*	0*	0	(21,225)*	(1,920)*	483*	2,673	664*	5,741*	5,349*	5,401	(6,889)*
Proceeds from issuing common stock	0*	—	0	0*	0*	—	—	—	—	—	—	—
Net cash from financing activities	0*	(486)*	15,248	251*	0*	0*	0	265*	0*	0*	(1)	4,919*
Net change in cash	(2,551)*	(2,946)*	28,821	(24,701)*	(938)*	(1,845)*	(21)	(2,742)*	4,481*	3,188*	2,259	(3,879)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palisade Bio	125,172	500	(7,603)*	174.3M	16.5 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.